Kosten TR, Baxter LE. Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. Am J Addict. 2019; 28:(2)55-62

McAuley A, Fraser R, Glancy M, Yeung A, Jones HE, Vickerman P, Hutchinson SJ. Mortality among individuals prescribed opioid-agonist therapy in Scotland, UK, 2011–20: a national retrospective cohort study. Lancet Public Health. 2023; 8:(7)e484-e493

National Institute for Health and Care Excellence. Poisoning, emergency treatment. 2023a. (accessed 12 September 2023)

National Institute for Health and Care Excellence. Substance dependence. 2023b. (accessed 12 September 2023)

National Institute for Health and Care Excellence. Naloxone hydrochloride. 2023c. (accessed 12 September 2023)

Speakman EM, Hillen P, Heyman I ‘I'm not going to leave someone to die’: carriage of naloxone by police in Scotland within a public health framework: a qualitative study of acceptability and experiences. Harm Reduction Journal. 2023;

Naloxone hydrochloride for acute opioid events

02 October 2023
Volume 5 · Issue 10

As part of public health initiatives, a number of countries now provide naloxone kits for use by first responders in an effort to tackle drug-related deaths within communities (Speakman et al, 2023). For those who are opioid dependent, ‘take home naloxone’ may be administered in the event of an accidental overdose, and prior to hospital admission (McAuley et al, 2023).

Naloxone hydrochloride is an opioid receptor antagonist that blocks or rapidly reverses the effects of drugs such as morphine, heroin, methadone or fentanyl. An overdose of an opioid can suppress the central nervous system, resulting in respiratory depression, bradycardia and loss of consciousness. Rapid administration of naloxone is indicated as first-line medication to reverse these symptoms which can be fatal if not treated promptly (Table 1).

Frequent monitoring of the patient's respiratory rate and level of consciousness post-naloxone administration should be undertaken as naloxone has a shorter duration of action than many opioids and repeated doses may be required (NICE, 2023a).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month